Trial Profile

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abelacimab (Primary) ; Abelacimab (Primary) ; Apixaban
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Registrational; Therapeutic Use
Acronyms ASTER
Sponsors Anthos Therapeutics

28 Aug 2025 Status changed from recruiting to active, no longer recruiting.
11 Feb 2025 According to an Anthos Therapeutics media release,data from this trials are expected in the second half of 2026.
31 Oct 2024 Planned End Date changed from 1 Sep 2025 to 1 Feb 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com